ClinicalTrials.gg

Program

Telmisartan

Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.

Furthest: phase 4, since May 2, 2002130 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim900 open or runningphase 4since May 2, 2002May 2, 2002none ahead
Chong Kun Dang Pharmaceutical122 open or runningphase 4since Mar 9, 2023May 20, 2010none ahead
Yuhan81 open or runningphase 4since Nov 10, 2016May 29, 2014none ahead
IlDong Pharmaceutical40 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceutical30 open or runningphase 3since Mar 8, 2017Mar 9, 2015none ahead
Daewon Pharmaceutical20 open or runningphase 3since Oct 12, 2016Oct 12, 2016none ahead
George Medicines PTY20 open or runningphase 3since Aug 15, 2020Aug 15, 2020none ahead
HK inno.N20 open or runningphase 1since Aug 25, 2021Aug 25, 2021none ahead
Daewoong Pharmaceutical10 open or runningphase 1since Mar 4, 2013Mar 4, 2013none ahead
dongkoo-bio-pharma10 open or runningphase 1since Feb 8, 2018Feb 8, 2018none ahead
Hanlim Pharm.10 open or runningphase 3since Dec 2, 2020Dec 2, 2020none ahead
Huons Global11 open or runningphase 1since Aug 5, 2026Aug 5, 2026Apr 2027phase 1 · NCT07784608
Pharmtechnology10 open or runningphase 1since Oct 8, 2018Oct 8, 2018none ahead
samil-pharmaceutical-co-ltd10 open or runningphase 1since Oct 13, 2015Oct 13, 2015none ahead
thpharm-corp10 open or runningphase 1since Sep 8, 2023Sep 8, 2023none ahead

Also a collaborator on its studies: linical-korea, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Aug 12, 2014.

  1. Aug 15, 2020George Medicines PTY's first studies: 2 phase 3 studies in HypertensionNew to George Medicines PTYGeorge Medicines PTY · NCT04518306, NCT04518293
  2. Dec 2, 2020Hanlim Pharm.'s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
  3. Apr 29, 2021Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT04883658 · 62 enrolled · Korea, Republic of
  4. Aug 25, 2021HK inno.N's first study: phase 1 study in HypertensionNew to HK inno.NHK inno.N · NCT05040880 · 46 enrolled · Korea, Republic of
  5. Jan 4, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05192356 · 63 enrolled · Korea, Republic of
  6. Jan 23, 2022Phase 1 study in HypertensionHK inno.N · NCT05223101 · 46 enrolled · Korea, Republic of
  7. Sep 18, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05549401 · 32 enrolled · Korea, Republic of
  8. Feb 20, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05749861 · 65 enrolled · Korea, Republic of
  9. Mar 9, 2023Phase 4 study in Essential HypertensionChong Kun Dang Pharmaceutical · NCT05843162 · 116 planned
  10. Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
  11. Sep 8, 2023thpharm-corp's first study: phase 1 study in HypertensionNew to thpharm-corpthpharm-corp · NCT06063109 · 51 enrolled · South Korea
  12. Oct 29, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT06112678 · 63 enrolled · Korea, Republic of
  13. May 22, 2024Phase 4 study in Diabetic NephropathiesChong Kun Dang Pharmaceutical · NCT06431477 · 98 planned · Korea, Republic of
  14. Aug 5, 2026Huons Global's first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea

Ahead

  1. Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The newest 60 of 130 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07784608Drug-drug Interactions · South Korea1Not yet recruitingHuons GlobalApr 202728
NCT06431477Diabetic Nephropathies · Korea, Republic of4RecruitingChong Kun Dang PharmaceuticalOct 31, 202598
NCT06112678Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalFeb 19, 202463
NCT06063109Hypertension · South Korea1Completedthpharm-corpNov 9, 202351
NCT06041529Essential Hypertension · South Korea4Active, not recruitingYuhanFeb 28, 2026198
NCT05843162Essential Hypertension4Not yet recruitingChong Kun Dang PharmaceuticalDec 31, 2023116
NCT05749861Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJun 7, 202365
NCT05549401Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalNov 30, 202232
NCT05223101Hypertension · Korea, Republic of1UNKNOWNHK inno.NJul 202246
NCT05192356Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalMay 8, 202263
NCT05040880Hypertension · Korea, Republic of1CompletedHK inno.NOct 31, 202146
NCT04883658Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJul 20, 202162
NCT04659070Hypertension · Korea, Republic of3UNKNOWNHanlim Pharm.May 19, 2022156
NCT04518306Hypertension · United States, Australia, Nigeria and more3CompletedGeorge Medicines PTYSep 19, 2023755
NCT04518293Hypertension · United States, Australia, Czechia and more3CompletedGeorge Medicines PTYAug 11, 20231,385
NCT04258865Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalApr 26, 202030
NCT04158076Hypercholesterolemia · Korea, Republic of3CompletedYuhanJan 14, 2021131
NCT03889145Healthy1CompletedIlDong PharmaceuticalFeb 19, 201430
NCT03872232Hypercholesterolemia · Korea, Republic of3CompletedYuhanAug 12, 2020180
NCT03705533Bioequivalence · Canada1CompletedPharmtechnologyDec 16, 201826
NCT03662620Hypertension · Korea, Republic of1CompletedYuhanDec 8, 201867
NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of3CompletedIlDong PharmaceuticalJun 16, 2017134
NCT03550859Renal Insufficiency, Chronic · Korea, Republic of4UNKNOWNYuhanDec 2021374
NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of1CompletedJeil PharmaceuticalJul 12, 201732
NCT03438955Hyperlipidemias · Korea, Republic of1UNKNOWNdongkoo-bio-pharmaJul 31, 201848
NCT03088254Dyslipidemia With Hypertension · Korea, Republic of3CompletedJeil PharmaceuticalJul 31, 2017126
NCT02968160Metabolic Syndrome · Korea, Republic of4TerminatedYuhanFeb 201855
NCT03210532Hypertension · Korea, Republic of3CompletedDaewon PharmaceuticalSep 2017129
NCT02933658Hypertension1CompletedDaewon PharmaceuticalNov 201571
NCT02738632Essential Hypertension · Korea, Republic of3CompletedIlDong PharmaceuticalAug 2016300
NCT02579356Essential Hypertension · Korea, Republic of1Completedsamil-pharmaceutical-co-ltdAug 201448
NCT02387619Hypertension · Korea, Republic of1CompletedJeil PharmaceuticalMar 201541
NCT02276391Healthy1CompletedBoehringer IngelheimOct 200864
NCT02269176Hypertension3CompletedBoehringer IngelheimJan 2001330
NCT02263989Healthy1CompletedBoehringer IngelheimApr 200730
NCT02262858Healthy1CompletedBoehringer IngelheimOct 200568
NCT02262793Healthy1CompletedBoehringer IngelheimJul 200424
NCT02262780Healthy1CompletedBoehringer IngelheimFeb 15, 200420
NCT02262650Healthy1CompletedBoehringer IngelheimMay 200424
NCT02262624Healthy1CompletedBoehringer IngelheimFeb 200536
NCT02262598Healthy1CompletedBoehringer IngelheimOct 200430
NCT02262585Healthy1CompletedBoehringer IngelheimAug 200230
NCT02262572Healthy1CompletedBoehringer IngelheimAug 200324
NCT02262559Healthy1CompletedBoehringer IngelheimAug 200230
NCT02261129Healthy1CompletedBoehringer IngelheimDec 200864
NCT02261116Healthy4CompletedBoehringer IngelheimAug 200224
NCT02261064Healthy1CompletedBoehringer IngelheimFeb 200932
NCT02260089Hypertension4CompletedBoehringer IngelheimJul 2002134
NCT02259829Healthy1CompletedBoehringer IngelheimNov 200784
NCT02259816Healthy1CompletedBoehringer IngelheimAug 200638
NCT02259803Healthy1CompletedBoehringer IngelheimNov 200730
NCT02259790Healthy1CompletedBoehringer IngelheimAug 200730
NCT02242812Hypertension4TerminatedBoehringer IngelheimOct 200424
NCT02242370Hypertension4CompletedBoehringer IngelheimNov 20003,045
NCT02242344Hypertension2CompletedBoehringer IngelheimSep 200777
NCT02242318Hypertension4CompletedBoehringer IngelheimSep 2002440
NCT02233218Healthy Male Volunteer · Korea, Republic of1CompletedYuhanOct 201460
NCT02218684Healthy1CompletedBoehringer IngelheimNov 199827
NCT02215005Healthy1CompletedBoehringer IngelheimSep 200742
NCT02214992Healthy1CompletedBoehringer IngelheimJun 200784

How it is read

Names in the registry

  • “Telmisartan”, 38 entries
  • “telmisartan”, 7 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Telmisartan 40 mg”, 6 entries
  • “Low dose of telmisartan”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.